You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD30 Positive Mature T Cell Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

Withdrawn
  • T Cell Lymphoma
  • Brentuximab Vedotin
  • Kansas City, Kansas
    The University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023

Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Oct 11, 2022

Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

Active, not recruiting
  • Anaplastic Large Cell Lymphoma
  • +4 more
  • Duarte, California
  • +3 more
Jul 21, 2022

T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)

Not yet recruiting
  • T-Cell Lymphoma
  • (no location specified)
Jul 22, 2022

T-Cell Lymphoma Trial (Brentuximab vedotin)

Not yet recruiting
  • T-Cell Lymphoma
  • Brentuximab vedotin
  • (no location specified)
Jun 30, 2022

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)

Recruiting
  • Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
  • Classical Hodgkin Lymphoma
  • CD30.CAR-EBVST cells
  • Houston, Texas
  • +1 more
Jul 20, 2022

Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

Not yet recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Peripheral T Cell Lymphoma
  • (no location specified)
May 30, 2023

Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Oct 13, 2023

Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • CAR-T Therapy
  • Hefei, Anhui, China
  • +7 more
Jul 31, 2023

Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Lymphoma
  • CD70-targeting CAR-T cells
  • Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 9, 2023

NK/T Cell Lymphoma Nos Trial (Brentuximab Vedotin in Combination with Tislelizumab)

Not yet recruiting
  • NK/T Cell Lymphoma Nos
  • Brentuximab Vedotin in Combination with Tislelizumab
  • (no location specified)
Apr 6, 2022

Lymphoma Trial in China (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin)

Not yet recruiting
  • Lymphoma
  • Brentuximab Vedotin
  • +3 more
  • Beijing, China
  • +15 more
Jan 4, 2023

A Study of People With CD30 Positive Lymphoma in China

Not yet recruiting
  • Lymphoma
    • (no location specified)
    Aug 17, 2022

    Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • CD19 specific Chimeric Antigen Receptor T Cell
    • Columbus, Ohio
      Nationwide Children's Hospital
    Mar 9, 2023

    Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)

    Recruiting
    • Lymphoma
    • +7 more
    • ATLCAR.CD30 cells
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Dec 2, 2022

    Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

    Recruiting
    • Recurrent Anaplastic Large Cell Lymphoma
    • +9 more
    • Anti-CD30/CD16A Monoclonal Antibody AFM13
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 9, 2022

    Peripheral T Cell Lymphoma Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 T cells, Bendamustine, Fludarabine)

    Recruiting
    • Peripheral T Cell Lymphoma
    • ATLCAR.CD30 T cells
    • +3 more
    • Chapel Hill, North Carolina
    • +1 more
    Mar 4, 2022

    T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

    Recruiting
    • T-cell Acute Lymphoblastic Leukemia
    • +3 more
    • Universal CD7-specific CAR gene-engineered T cells
    • Beijing, Beijing, China
    • +2 more
    Aug 17, 2023

    Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

    Not yet recruiting
    • Cancer
    • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
    • Fludarabine (30 mg/m^2)
    • +2 more
    • (no location specified)
    Jul 25, 2023

    Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,

    Recruiting
    • Cutaneous T-Cell Lymphoma
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 23, 2023

    T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7

    Recruiting
    • T Lymphoblastic Leukemia/Lymphoma
    • +4 more
    • anti-CD7 CAR-T cells
    • Shanghai, China
      Xianmin General Song
    Aug 29, 2022

    B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

    Recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • +2 more
    • CD19/CD22-bispecific CAR-T cells
    • Beijing, Beijing, China
      Liang Wang
    Oct 7, 2023

    T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

    Not yet recruiting
    • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
    • CD7-CART01
    • (no location specified)
    Sep 26, 2023

    Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

    Recruiting
    • Extranodal NK T Cell Lymphoma
    • NK-Cell Leukemia
    • Anti-CD56 CAR T
    • Xuzhou, Jiangsu, China
      The Affiliated Hospital of Xuzhou Medical University
    Jul 10, 2023